



Control Α α IR3 B NVP-ADW742 C anti-IL-6R D 20% serum E αIR3+20%serum F NVP-ADW742+20%serum G anti-IL-6R+20%serum H

Figure 2



5

0




10

Days of treatment

15

20



Densitometric value (% of respective control)









Figure 5














Fig.9





Figure 10

Transcriptional signature of IGF-1 stimulation

	Upregulated	Downregulated
Cell signaling	CK-1 and -2, chemokine-like factor 1, CXCR-4, Aurora-1, Aurora-2, SAK, SGK, PP2A, some PP1 subunits, PP4, GADD-α and -β, PTEN, CD71	FLIP, c-raf1 (but upregulated at protein level), Gas6, IGF-1, IGF-1R, IGF-2R, IFN-a, b, omega receptor, IL-2Rγ, gp130, RAR-α, RAR-γ, BCMA, TNF-a-induced protein
Apoptosis regulation	Survivin, Bad, PCD5, PCD8, PCD10, VDAC3	Bcl-2 (no effect on protein level on short- to mid-term stimulation), Mcl- 1 (stable protein levels), TOSO
Cell cycle control	Ki-67, CDC -2,-5, -6, -7, -20, -23, -25, -28, -45, cyclins A2, B1, B2, E1, F, G1, (D1, D2, D3), CDK2, CDK4, PCNA, replication factor C (multiple subunits), replication proteins A1, A2, and A3, ASK, CHK1, G2-S-expressed 1, stathmin/oncoprotein 1, Wee1+	
Microenvironmental interactions	RHAMM, integrin aE, ADAM-8, -22, -28	Integrin α8, αL, β1, β5
Wnt signaling pathway		Frizzled-related protein, WNT10B, WNT5B
Transcriptional/translat ional control	ATF-1, ATF-3, E2F-3, eIF-1, -2, -3, -4 and -5, multiple ribosomal proteins, DP-1, c-myb, XBP-1	c-myc
DNA synthesis/repair enzymes	BUB1, BUB3, DNA-PK, deoxycytidine kinase, deoxythymidylate kinase, DHFR, dyskerin, dUTP pyrophosphatase, MCM 2, 3, 4, 5, 6, 7, MSH-2, -3, -6, RAD51, guanine monophosphate synthase, RRM1, RRM2, TOPOIIA, XRCC	
Histone regulation	HDAC1, HAT1	
Oncogenes	DEK, liposarcoma fusion gene t(12;16), SET translocation	
Heat shock proteins / Chaperones	Hsp90, -70, 105, 27, 110, 14-3-3, chaperonin TCP1	·
Immune system interactions		MHC class IE and II (less extensive changes in comparison to IL-6 or co-Cx)
Nucleocytoplasmic transport and other carrier proteins	Exportin, nucleoporins 50, 54, 62, 88, 98, 155, karyopherins b1, b3, a1, a2, a3, a4, kinesin-like 1, 2, 4, 5, 6, 7 (multiple Rab, Ran proteins), transportins	
Metabolism	F0F1 ATPase mitochondrial, ornithine decarboxylase, HMG-CoA reductase, calmodulin-1 and -2	
Ubiquitin/Proteasome pathway	POH, Multiple 26S subunit genes (26S subunits α1, α 2, α 3, α 5, α 7, β1, β2, β3, β5, β6, β7, β 8, ATPase 1, 2, 3, 4, 5, 6, non-ATPase 1, 2, 4, 7, 8, 11, 12, 13), UCEs, USPs	Some USPs (-9, -11)






Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19





Figure 20



WO 2005/082415 PCT/US2005/005922

Figure 21




Figure 22




Figure 23




Figure 24




Figure 25





Figure 26







Figure 27








Figure 30

ADW742

5-(3-Benzyloxy-phenyl)-7-(3-pyrroli din-1-ylmethyl-cyclobutyl)-7H-pyrro lo[2,3-d]pyrimidin-4-ylamine

AEW541

7-(3-Azetidin-1-ylmethyl-cyclobutyl)-5-(3-benzyloxy-phenyl)-7H-pyrrolo [2,3-d]pyrimidin-4-ylamine